Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 28, 2013; 19(32): 5381-5384
Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5381
Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5381
1-yr prior to consumption | During consumption | 1-yr after consumption | |
AST (UI/L) (normal < 40) | |||
Case 1 | 25 | 182 | 71 |
Case 2 | 36 | 161 | 36 |
ALT (UI/L) (normal < 40) | |||
Case 1 | 33 | 282 | 85 |
Case 2 | 53 | 162 | 37 |
GGT (UI/L) (normal < 40) | |||
Case 1 | 32 | 150 | 77 |
Case 2 | 18 | 31 | 15 |
AP (U/L) (normal < 290) | 229 | 219 | |
Case 1 | 240 | 183 | 213 |
Case 2 | 144 | ||
Total bilirubin (mg/dL) (normal < 1.2) | |||
Case 1 | 0.3 | 0.8 | 0.4 |
Case 2 | 0.8 | 0.9 | 0.9 |
- Citation: Cerda C, Bruguera M, Parés A. Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease. World J Gastroenterol 2013; 19(32): 5381-5384
- URL: https://www.wjgnet.com/1007-9327/full/v19/i32/5381.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i32.5381